drugset / Trial / NCT06631417

A Study in Healthy People to Test How 2 Different Doses of BI 1291583 Are Taken up in the Body When Given in 3 Different Formulations

NCT06631417

Phase 1 Completed 30 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The main objective of this trial is to investigate the relative bioavailability of two different formulations of BI 1291583 (test formulations) compared to BI 1291583 reference formulation administered at two different dose levels.

Timeline

Start
2024-10-22
Primary completion
2025-01-10
Completion
2025-05-14

Drugs

EvaluationDrugModalityDoseRoute
Subject BI 1291583 Unknown Oral

Indications

No indication recorded.